Medical devices continue to be a strong growth driver for Abbott, as the company battles its ongoing sales slump in diagnostics, which accelerated in the third quarter. Third-quarter revenue for its ...
(Reuters) -Abbott warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs, and the government's foreign ...
The Food and Drug Administration issued a warning late Thursday over the accuracy of the highly-touted Abbott instant coronavirus test. Specifically, the FDA said that the test has caused some false ...
*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. The maker of a rapid coronavirus test widely used across the United States and distributed by the federal government has warned ...
Hosted on MSN
Abbott Reports 12% Growth in Device Sales
Abbott Laboratories(NYSE:ABT) reported its second-quarter 2025 results on July 17, 2025, posting 7.5% organic sales growth (excluding COVID testing), 12% medical device growth, and adjusted EPS of ...
Abbott Laboratories narrowed its full-year outlook as sales of COVID-19 tests slide. COVID-19 test sales in the second quarter dropped 46% from the year before. Second-quarter earnings and revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback